Index RUT P/E - EPS (ttm) -2.36 Insider Own 6.96% Shs Outstand 77.75M Perf Week -2.40%
Market Cap 633.77M Forward P/E - EPS next Y -1.77 Insider Trans -0.43% Shs Float 72.35M Perf Month 10.28%
Income -197.55M PEG - EPS next Q -0.63 Inst Own 99.81% Short Float 11.16% Perf Quarter -48.81%
Sales 0.00M P/S - EPS this Y -17.65% Inst Trans 26.68% Short Ratio 3.67 Perf Half Y -59.49%
Book/sh 5.45 P/B 1.50 EPS next Y 27.58% ROA -41.48% Short Interest 8.08M Perf Year -60.48%
Cash/sh 5.85 P/C 1.39 EPS next 5Y 4.23% ROE -46.28% 52W Range 6.98 - 24.17 Perf YTD -6.43%
Dividend Est. - P/FCF - EPS past 5Y -3.94% ROI -45.21% 52W High -66.28% Beta 0.84
Dividend TTM - Quick Ratio 11.47 Sales past 5Y 0.00% Gross Margin - 52W Low 16.76% ATR (14) 0.49
Dividend Ex-Date - Current Ratio 11.47 EPS Y/Y TTM -16.69% Oper. Margin - RSI (14) 45.18 Volatility 5.51% 6.63%
Employees 142 Debt/Eq 0.04 Sales Y/Y TTM - Profit Margin - Recom 1.44 Target Price 27.69
Option/Short Yes / Yes LT Debt/Eq 0.03 EPS Q/Q -25.19% Payout - Rel Volume 0.38 Prev Close 8.29
Sales Surprise - EPS Surprise -0.62% Sales Q/Q - Earnings Feb 26 AMC Avg Volume 2.20M Price 8.15
SMA20 -1.58% SMA50 -4.51% SMA200 -50.74% Trades
Volume 831,642 Change -1.69%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-06-25 Downgrade BTIG Research
Buy → Neutral
Oct-24-24 Initiated UBS
Buy
$27
Oct-14-24 Downgrade Stifel
Buy → Hold
$26 → $19
Dec-22-23 Initiated Mizuho
Buy
$26
Aug-11-23 Initiated BofA Securities
Buy
$31
Jul-27-23 Initiated Scotiabank
Sector Perform
$10.50
May-17-23 Initiated BTIG Research
Buy
$31
Jan-31-23 Initiated Stifel
Buy
$25
Jul-12-22 Initiated Cantor Fitzgerald
Overweight
$30
Feb-15-22 Initiated Jefferies
Buy
$35
May-05-21 Resumed Credit Suisse
Outperform
$42
Apr-26-21 Resumed Credit Suisse
Outperform
$42
Dec-07-20 Reiterated H.C. Wainwright
Buy
$40 → $45
Dec-03-20 Initiated Stifel
Buy
$45
Nov-05-20 Downgrade Piper Sandler
Overweight → Neutral
Jul-07-20 Initiated Credit Suisse
Outperform
$27
May-05-20 Initiated Barclays
Overweight
$24
Jul-18-19 Initiated Deutsche Bank
Buy
$28
Nov-09-18 Initiated Piper Jaffray
Overweight
Aug-01-18 Initiated H.C. Wainwright
Buy
$31
Show Previous Ratings
Feb-19-25 07:30AM
Feb-07-25 07:30AM
Feb-05-25 04:01PM
Jan-06-25 04:30PM
Dec-09-24 07:00AM
01:25PM
Loading…
Dec-04-24 01:25PM
Dec-02-24 07:30AM
Nov-25-24 07:30AM
Nov-23-24 10:42AM
Nov-22-24 05:30AM
Nov-21-24 04:15PM
(Investor's Business Daily) -36.77%
09:05AM
(Investor's Business Daily)
06:37AM
(Pharmaceutical Technology)
Nov-20-24 05:00PM
Nov-08-24 04:01PM
05:15PM
Loading…
Nov-07-24 05:15PM
(Associated Press Finance)
04:05PM
Nov-05-24 09:09AM
Oct-31-24 07:30AM
Oct-29-24 08:00AM
Oct-24-24 07:30AM
Oct-23-24 07:30AM
Oct-09-24 05:54PM
Sep-30-24 06:30PM
Sep-17-24 07:30AM
Sep-10-24 07:30AM
Sep-05-24 12:01AM
Sep-02-24 05:22PM
Aug-08-24 04:44PM
(Associated Press Finance)
04:05PM
07:30AM
Loading…
07:30AM
Aug-01-24 07:30AM
Jul-05-24 07:30AM
Jun-24-24 07:30AM
Jun-17-24 09:00AM
Jun-07-24 07:30AM
May-29-24 07:30AM
May-14-24 11:44AM
07:30AM
May-08-24 08:30AM
07:30AM
May-06-24 10:14AM
May-03-24 07:30AM
04:03AM
May-02-24 08:58PM
04:48PM
(Associated Press Finance)
04:05PM
Apr-25-24 07:30AM
Apr-22-24 07:30AM
Apr-10-24 07:30AM
Apr-05-24 07:30AM
Mar-06-24 07:30AM
Mar-01-24 05:00PM
Feb-28-24 09:56AM
06:56AM
(Thomson Reuters StreetEvents)
Feb-27-24 04:44PM
04:10PM
(Associated Press Finance)
04:01PM
Feb-26-24 07:30AM
Feb-22-24 07:30AM
Feb-20-24 07:30AM
Feb-02-24 07:30AM
Feb-01-24 03:01PM
Jan-30-24 04:07PM
(Investor's Business Daily) +12.10%
07:00AM
Jan-24-24 04:22PM
(Investor's Business Daily) +46.13%
01:16PM
07:00AM
Dec-08-23 07:30AM
Nov-28-23 07:30AM
Nov-05-23 03:44PM
Nov-02-23 06:46PM
(GuruFocus.com) +5.38%
+7.01%
04:36PM
(Associated Press Finance)
04:01PM
07:30AM
Oct-30-23 07:30AM
Oct-26-23 04:05PM
Oct-19-23 07:30AM
Oct-17-23 04:05PM
Oct-09-23 02:03AM
Oct-04-23 12:00PM
07:30AM
Sep-28-23 07:30AM
Sep-19-23 07:30AM
Aug-14-23 07:30AM
Aug-03-23 04:38PM
(Associated Press Finance)
04:05PM
Jul-27-23 07:30AM
Jul-11-23 09:35AM
Jun-14-23 07:00AM
Jun-13-23 04:01PM
Jun-11-23 03:45AM
Jun-05-23 08:02PM
May-30-23 07:30AM
May-23-23 07:30AM
May-13-23 11:51AM
May-11-23 09:35AM
(Thomson Reuters StreetEvents) +8.30%
May-10-23 04:17PM
04:03PM
May-09-23 07:30AM
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DOYLE THOMAS JAMES SVP, Finance & Accounting Jan 28 '25 Sale 7.87 4,949 38,958 88,193 Jan 28 08:54 PM Leoni Mollie Chief Medical Officer Jan 28 '25 Sale 7.87 4,963 39,068 88,253 Jan 28 08:39 PM Bair Teresa Brophy Chief Legal Officer Jan 28 '25 Sale 7.87 7,281 57,315 107,948 Jan 28 08:38 PM FORD KATHLEEN Chief Operating Officer Jan 28 '25 Sale 7.87 1,817 14,303 21,367 Jan 28 08:38 PM Burrows Francis Chief Scientific Officer Jan 28 '25 Sale 7.87 2,166 17,051 20,705 Jan 28 08:38 PM Powl Brian T. Chief Commercial Officer Jan 28 '25 Sale 7.87 1,583 12,461 59,667 Jan 28 08:38 PM LEONI MOLLIE Officer Jan 28 '25 Proposed Sale 7.77 4,963 38,563 Jan 28 08:37 PM BAIR TERESA BROPHY Officer Jan 28 '25 Proposed Sale 7.77 7,281 56,573 Jan 28 08:37 PM FORD KATHLEEN Officer Jan 28 '25 Proposed Sale 7.77 1,817 14,118 Jan 28 08:37 PM DOYLE THOMAS JAMES Officer Jan 28 '25 Proposed Sale 7.77 4,949 38,454 Jan 28 08:37 PM BURROWS FRANCIS Officer Jan 28 '25 Proposed Sale 7.77 2,166 16,830 Jan 28 08:37 PM POWL BRIAN T Officer Jan 28 '25 Proposed Sale 7.77 1,583 12,300 Jan 28 08:36 PM FORD KATHLEEN Chief Operating Officer Nov 18 '24 Sale 16.03 526 8,434 23,184 Nov 19 04:05 PM FORD KATHLEEN Officer Nov 18 '24 Proposed Sale 15.99 526 8,410 Nov 18 04:03 PM Bair Teresa Brophy Chief Legal Officer May 20 '24 Sale 22.15 2,615 57,916 68,979 May 20 06:30 PM
Index RUT P/E - EPS (ttm) -1.65 Insider Own 14.07% Shs Outstand 113.88M Perf Week 23.60%
Market Cap 175.97M Forward P/E - EPS next Y -1.69 Insider Trans 0.23% Shs Float 97.86M Perf Month 17.05%
Income -178.23M PEG - EPS next Q -0.44 Inst Own 81.33% Short Float 13.15% Perf Quarter -23.51%
Sales 13.45M P/S 13.08 EPS this Y 0.43% Inst Trans -7.04% Short Ratio 4.31 Perf Half Y -57.44%
Book/sh 3.18 P/B 0.49 EPS next Y -3.29% ROA -34.32% Short Interest 12.87M Perf Year -79.56%
Cash/sh 2.61 P/C 0.59 EPS next 5Y 1.90% ROE -46.59% 52W Range 1.04 - 8.83 Perf YTD -6.36%
Dividend Est. - P/FCF - EPS past 5Y -6.65% ROI -39.22% 52W High -82.50% Beta 2.25
Dividend TTM - Quick Ratio 8.29 Sales past 5Y 77.60% Gross Margin -41.55% 52W Low 48.56% ATR (14) 0.16
Dividend Ex-Date - Current Ratio 8.29 EPS Y/Y TTM 6.37% Oper. Margin -1462.06% RSI (14) 54.46 Volatility 16.14% 9.63%
Employees 181 Debt/Eq 0.27 Sales Y/Y TTM -87.34% Profit Margin -1325.43% Recom 2.44 Target Price 6.86
Option/Short Yes / Yes LT Debt/Eq 0.25 EPS Q/Q 11.67% Payout - Rel Volume 1.05 Prev Close 1.71
Sales Surprise 147.44% EPS Surprise 3.96% Sales Q/Q 58.13% Earnings Nov 12 AMC Avg Volume 2.99M Price 1.54
SMA20 13.71% SMA50 -2.06% SMA200 -48.74% Trades
Volume 3,138,146 Change -9.65%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-18-24 Upgrade BofA Securities
Underperform → Neutral
Jun-17-24 Upgrade Piper Sandler
Neutral → Overweight
$4 → $6
Mar-27-23 Resumed Wells Fargo
Equal Weight
$6
Jan-24-23 Downgrade H.C. Wainwright
Buy → Neutral
$115 → $7
Jan-06-23 Downgrade Wedbush
Outperform → Neutral
$42 → $7
Jan-06-23 Downgrade Truist
Buy → Hold
$46 → $7
Jan-06-23 Downgrade Stifel
Buy → Hold
$107 → $5.30
Jan-06-23 Downgrade Piper Sandler
Overweight → Neutral
$71 → $12
Jan-06-23 Downgrade Cowen
Outperform → Market Perform
Jan-06-23 Downgrade BofA Securities
Buy → Underperform
$72 → $4
Jan-06-23 Downgrade BMO Capital Markets
Outperform → Market Perform
$20 → $7
Jan-03-23 Downgrade Guggenheim
Buy → Neutral
Dec-22-22 Downgrade Oppenheimer
Outperform → Perform
Dec-15-22 Initiated Goldman
Sell
$10
Nov-04-22 Resumed Cantor Fitzgerald
Overweight
$98 → $45
Oct-10-22 Initiated Canaccord Genuity
Buy
$42
Aug-18-22 Resumed Wells Fargo
Overweight
$90
Jul-28-22 Initiated Needham
Hold
Jul-11-22 Upgrade BMO Capital Markets
Market Perform → Outperform
$50 → $47
Jun-03-22 Initiated Robert W. Baird
Neutral
$28
Show Previous Ratings
Feb-17-25 10:00AM
Feb-14-25 04:01PM
(GlobeNewswire) +11.81%
+7.75%
Feb-04-25 04:01PM
Jan-03-25 04:01PM
Dec-12-24 11:30AM
04:01PM
Loading…
Dec-09-24 04:01PM
Dec-03-24 04:01PM
Dec-02-24 09:55AM
(Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM
Nov-26-24 04:01PM
(GlobeNewswire) +10.74%
+18.28%
Nov-18-24 08:05AM
08:00AM
Nov-12-24 05:20PM
04:18PM
(Associated Press Finance)
04:01PM
01:30PM
Loading…
Nov-09-24 01:30PM
Nov-08-24 04:01PM
(GlobeNewswire) -5.10%
+5.79%
Nov-04-24 04:01PM
Oct-02-24 04:01PM
Sep-12-24 04:01PM
11:30AM
Aug-16-24 12:00PM
Aug-13-24 05:25PM
04:25PM
(Associated Press Finance)
04:05PM
Aug-02-24 04:01PM
(GlobeNewswire) -5.12%
-9.50%
Jul-31-24 08:00AM
Jul-21-24 05:37AM
Jul-02-24 04:01PM
Jun-04-24 04:01PM
04:01PM
Loading…
May-29-24 04:01PM
May-13-24 10:48AM
May-10-24 02:50PM
10:36AM
08:22AM
May-09-24 08:58PM
05:25PM
04:21PM
(Associated Press Finance)
04:01PM
08:30AM
May-06-24 08:00AM
May-03-24 04:30PM
Apr-22-24 04:30PM
Apr-06-24 02:17AM
Apr-04-24 11:30PM
Apr-03-24 08:00AM
Apr-02-24 04:01PM
Mar-27-24 11:30AM
Mar-19-24 08:44AM
Mar-05-24 04:01PM
Mar-01-24 08:09AM
08:00AM
Feb-27-24 09:16AM
08:07AM
(Thomson Reuters StreetEvents)
Feb-26-24 05:10PM
04:35PM
04:08PM
(Associated Press Finance)
04:01PM
Feb-21-24 09:21AM
Feb-19-24 10:00AM
Feb-15-24 08:00AM
Feb-02-24 04:01PM
Jan-30-24 07:54AM
Jan-29-24 02:53PM
Jan-08-24 08:00AM
Dec-22-23 12:00PM
Dec-18-23 02:58PM
Dec-13-23 05:00PM
(GlobeNewswire) +11.67%
+11.19%
Dec-08-23 11:30AM
Nov-09-23 01:18PM
Nov-08-23 06:18PM
04:08PM
(Associated Press Finance)
04:01PM
Oct-25-23 08:00AM
Sep-15-23 06:01AM
Sep-07-23 11:30AM
Aug-31-23 08:00AM
Aug-29-23 07:30AM
Aug-09-23 12:12PM
11:04AM
(Thomson Reuters StreetEvents)
Aug-08-23 05:15PM
04:11PM
(Associated Press Finance)
04:01PM
Jul-28-23 08:00AM
Jul-22-23 08:35AM
Jul-01-23 10:33AM
Jun-16-23 03:53PM
Jun-14-23 06:42AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-04-23 08:27AM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-25-23 10:49AM
May-08-23 06:05AM
May-04-23 11:59AM
11:22AM
(Thomson Reuters StreetEvents)
May-03-23 05:15PM
04:11PM
04:01PM
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bressi Jerome Charles See Remarks Jan 10 '25 Sale 1.55 5,980 9,269 270,203 Jan 13 04:06 PM TAHL CINDY See Remarks Jan 10 '25 Sale 1.55 5,654 8,764 336,707 Jan 13 04:05 PM Valamehr Bahram President and CEO Jan 10 '25 Sale 1.54 8,705 13,406 349,364 Jan 13 04:04 PM Valamehr Bahram Officer Jan 10 '25 Proposed Sale 1.54 8,705 13,447 Jan 10 03:20 PM Bressi Jerome Charles Officer Jan 10 '25 Proposed Sale 1.55 5,980 9,276 Jan 10 03:12 PM TAHL CINDY Officer Jan 10 '25 Proposed Sale 1.55 5,654 8,782 Jan 10 03:12 PM Redmile Group, LLC Director Dec 20 '24 Buy 1.68 397,964 668,580 12,884,277 Dec 26 09:00 PM Redmile Group, LLC Director Dec 20 '24 Sale 1.68 341,633 573,943 12,486,313 Dec 26 09:00 PM Redmile Group, LLC Director, 10% Stockholder Dec 20 '24 Proposed Sale 1.66 341,633 567,111 Dec 20 09:00 PM Xu Yuan Director Aug 06 '24 Sale 4.23 633 2,678 8,669 Aug 07 04:01 PM Xu Yuan Director Aug 06 '24 Proposed Sale 4.23 633 2,678 Aug 06 10:34 AM Dulac Edward J III Chief Financial Officer Mar 04 '24 Sale 7.77 2,447 19,013 101,479 Mar 05 04:24 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
